FDA Urges Early Communication of CMC Data Gaps for Breakthrough Therapies
This article was originally published in The Gold Sheet
FDA officials urged the pharmaceutical industry to communicate early on the reasons for missing CMC information for new drug applications for breakthrough therapies, such early notification helps them do better risk assessments.
You may also be interested in...
Genentech overcame objections from US FDA quality reviewers to win approval of Ocrevus for multiple sclerosis by adding release and stability testing and committing to resolving process control issues, while suspending plans to accelerate post-approval manufacturing changes.
By compressing clinical timelines, a FDASIA-mandated “breakthrough therapy” application process is pressuring FDA and industry to complete CMC reviews much more quickly. While FDA is emphasizing starting earlier and working harder, industry is talking more about the possibility of deferring some CMC activities post-submission or post-approval.
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”